Bicycle Therapeutics develops a novel class of medicines called Bicycle molecules, which are synthetic bicyclic peptides that combine the targeting precision of biologics with the favorable properties of small molecules. The company focuses its pipeline on precision-guided therapies for solid tumor cancers, including toxin conjugates and immune cell agonists. Its technology platform has led to multiple clinical-stage programs and collaborations with leading pharmaceutical companies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 10 | — | -60.8 | — |
| Q2 2025 | 2.9 | — | -79 | — |
| Q3 2025 | 11.7 | — | -59.1 | — |
| Q4 2025 | 48 | — | -20.1 | — |
| Q1 2026 | 0.9 | -91.1% | -60.8 | — |
| Q2 2026 | 0.6 | -78.5% | -50.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Strattec Security Corporation (STRT), Digital Asset Acquisition Corp. (DAAQ), Dynamix Corporation (DYNC), Security National Financial Corporation (SNFCA), Rocket Pharmaceuticals, Inc. (RCKT), Cabaletta Bio, Inc. (CABA)